Women in Saskatchewan who are battling ovarian cancer will soon have access to two new treatment options, according to an announcement from the province on Tuesday. Beginning Dec. 1, the provincial government will provide coverage for Elhere and Keytruda for women whose ovarian cancer has stopped responding to standard treatment like chemotherapy, making Saskatchewan the first province in Canada to do so. Both new treatments have helped patients live longer and delay progression of the disease, according to clinical studies. The province noted about eight to 10 patients in Saskatchewan each year are expected to benefit from access to both Keytruda and Elahere. “These two new treatments will provide hope for patients and families facing a difficult cancer diagnosis and ensure access to innovative, high-quality cancer care close to home,” Health Minister Jeremy Cockrill said in the province’s announcement. Ovarian cancer, the deadliest cancer of the female reproductive system, is frequently diagnosed at an advanced stage since symptoms can be hard to recognize. According to the province, many patients may respond to treatment initially, but options can be limited after chemotherapy stops working. Ovarian Cancer Canada CEO Tania Vrionis said she is proud to see Saskatchewan leading the way by making the treatment options available. “After months of advocacy from thousands of Canadians, this is a meaningful milestone for patients and families who have been waiting for new treatment options,” she said in the province’s announcement. “By publicly funding Elahere and Keytruda, Saskatchewan is helping remove financial barriers to treatments that offer women and their families more options, potentially more time and the chance to live more fully.” Those who believe they might be eligible for one of the new treatment options are asked to speak with their oncologist. As part of the 2026-27 budget, the Saskatchewan Cancer Agency received $308.6 million to support cancer prevention, early detection, diagnosis, treatment, research and patient support services.